{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:52:04Z","timestamp":1783464724186,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01742-w","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:58:09Z","timestamp":1775761089000},"page":"3263-3274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-6350","authenticated-orcid":false,"given":"Francesco","family":"Piscazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-9854","authenticated-orcid":false,"given":"Paola","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-4937","authenticated-orcid":false,"given":"Marco","family":"Ardig\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"1742_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17817","author":"GM Hren","year":"2025","unstructured":"Hren GM, Silva I, Adalsteinsson JA, Khattri S. Use of Deucravacitinib in cutaneous Lupus Erythematosus: two patient experiences at a combined rheumatology\u2013dermatology clinic. Int J Dermatol. 2025. https:\/\/doi.org\/10.1111\/ijd.17817.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1742_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","volume":"27","author":"LG Okon","year":"2013","unstructured":"Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391\u2013404. https:\/\/doi.org\/10.1016\/j.berh.2013.07.008.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1742_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81539","author":"EJ Matthew","year":"2025","unstructured":"Matthew EJ, Verma KK, Paulger B. Oral deucravacitinib for treatment-refractory cutaneous lupus erythematosus. Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.81539.","journal-title":"Cureus"},{"issue":"2","key":"1742_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double\u2010blind, placebo\u2010controlled trial. Arthritis Rheumatol. 2023;75(2):242\u201352. https:\/\/doi.org\/10.1002\/art.42391.","journal-title":"Arthritis Rheumatol"},{"key":"1742_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jdcr.2024.04.032","volume":"49","author":"N Ezeh","year":"2024","unstructured":"Ezeh N, Vleugels RA, Shahriari N. Discoid lupus erythematosus successfully treated with Deucravacitinib. JAAD Case Rep. 2024;49:59\u201361. https:\/\/doi.org\/10.1016\/j.jdcr.2024.04.032.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"1742_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1742_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/1346-8138.17074","volume":"51","author":"S Imafuku","year":"2024","unstructured":"Imafuku S, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open\u2010label, phase 3 trial. J Dermatol. 2024;51(3):365\u201379. https:\/\/doi.org\/10.1111\/1346-8138.17074.","journal-title":"J Dermatol"},{"issue":"19","key":"1742_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199447","volume":"26","author":"Y Mima","year":"2025","unstructured":"Mima Y, Yamamoto M, Iozumi K. Review of promising off-label use of Deucravacitinib. Int J Mol Sci. 2025;26(19):9447. https:\/\/doi.org\/10.3390\/ijms26199447.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1742_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133\u201345. https:\/\/doi.org\/10.1038\/s41584-021-00726-8.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1742_CR10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/jamadermatol.2023.0175","volume":"159","author":"K Shaw","year":"2023","unstructured":"Shaw K, et al. Assessment of clinical response to Anifrolumab in patients with refractory discoid lupus erythematosus. JAMA Dermatol. 2023;159(5):560. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0175.","journal-title":"JAMA Dermatol"},{"key":"1742_CR11","doi-asserted-by":"publisher","unstructured":"Kurz B, Ivanova I, Drexler K, Berneburg M, G\u00fcnther F, Niebel D. Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: a case report. J Eur Acad Dermatol Venereol. 2024;38(5):1\u20133. https:\/\/doi.org\/10.1111\/jdv.19667.","DOI":"10.1111\/jdv.19667"},{"key":"1742_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdcr.2023.07.030","volume":"39","author":"N Bouch\u00e9","year":"2023","unstructured":"Bouch\u00e9 N, Al-Saedy MA, Song EJ. Successful treatment of refractory subacute cutaneous lupus erythematosus with Deucravacitinib. JAAD Case Rep. 2023;39:93\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2023.07.030.","journal-title":"JAAD Case Rep"},{"key":"1742_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X241304891","volume":"13","author":"K Aw","year":"2025","unstructured":"Aw K, Gavigan G. Treatment of discoid Lupus Erythematosus scarring alopecia with deucravacitinib: a case report. SAGE Open Med Case Rep. 2025;13:2050313X241304891. https:\/\/doi.org\/10.1177\/2050313X241304891.","journal-title":"SAGE Open Med Case Rep"},{"key":"1742_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jdcr.2023.11.029","volume":"45","author":"A Zhang","year":"2024","unstructured":"Zhang A, Gaffney RG, Merola JF. Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib. JAAD Case Rep. 2024;45:110\u20132. https:\/\/doi.org\/10.1016\/j.jdcr.2023.11.029.","journal-title":"JAAD Case Rep"},{"key":"1742_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jdcr.2022.08.038","volume":"28","author":"JJ Park","year":"2022","unstructured":"Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Rep. 2022;28:133\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.038.","journal-title":"JAAD Case Rep"},{"issue":"6","key":"1742_CR16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","volume":"136","author":"J Wenzel","year":"2016","unstructured":"Wenzel J, Van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. 2016;136(6):1281\u20133. https:\/\/doi.org\/10.1016\/j.jid.2016.02.015.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1742_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. https:\/\/doi.org\/10.1038\/s41467-021-23361-z.","journal-title":"Nat Commun"},{"issue":"1","key":"1742_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.39818","volume":"69","author":"Y Furumoto","year":"2017","unstructured":"Furumoto Y, et al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol. 2017;69(1):148\u201360. https:\/\/doi.org\/10.1002\/art.39818.","journal-title":"Arthritis Rheumatol"},{"key":"1742_CR19","doi-asserted-by":"publisher","unstructured":"Elman SA, Mazori DR, Merola JF. Tofacitinib for refractory chilblain lupus erythematosus. Int J Dermatol. 2022;61(4):e156\u2013e157. https:\/\/doi.org\/10.1111\/ijd.15625.","DOI":"10.1111\/ijd.15625"},{"issue":"7","key":"1742_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamadermatol.2021.1198","volume":"157","author":"DR Mazori","year":"2021","unstructured":"Mazori DR, et al. Use of tofacitinib, 2%, ointment for periorbital discoid lupus erythematosus. JAMA Dermatol. 2021;157(7):880. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1198.","journal-title":"JAMA Dermatol"},{"key":"1742_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdcr.2021.09.030","volume":"20","author":"E Bonnardeaux","year":"2022","unstructured":"Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2022;20:61\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2021.09.030.","journal-title":"JAAD Case Rep"},{"issue":"10","key":"1742_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","volume":"78","author":"H You","year":"2019","unstructured":"You H, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441\u20133. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215455.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1742_CR23","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1093\/rheumatology\/keac309","volume":"61","author":"J Yang","year":"2022","unstructured":"Yang J, Li J, Shi L. Successful remission with tofacitinib in a patient with refractory bullous systemic lupus erythematosus. Rheumatology. 2022;61(11):e341\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/keac309.","journal-title":"Rheumatology"},{"key":"1742_CR24","unstructured":"LEO Pharma. US National Library of Medicine. ClinicalTrials.gov Identifier: NCT03958955. Efficacy and safety of twice-daily application of delgocitinib cream 20 mg\/g for 6 weeks in subjects with active discoid lupus erythematosus. https:\/\/clinicaltrials.gov\/study\/NCT03958955?cond=Discoid%20Lupus%20Erythematosus&intr=Delgocitinib&rank=1. Accessed 6 Mar 2025."},{"issue":"3","key":"1742_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/BOR.0000000000000704","volume":"32","author":"H Shi","year":"2020","unstructured":"Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208\u201314. https:\/\/doi.org\/10.1097\/BOR.0000000000000704.","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"1742_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103440","volume":"22","author":"L Ma","year":"2023","unstructured":"Ma L, et al. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2023;22(12):103440. https:\/\/doi.org\/10.1016\/j.autrev.2023.103440.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1742_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1586\/1744666X.2014.893827","volume":"10","author":"W-H Shao","year":"2014","unstructured":"Shao W-H, Cohen PL. The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets. Expert Rev Clin Immunol. 2014;10(5):573\u201382. https:\/\/doi.org\/10.1586\/1744666X.2014.893827.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1742_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1600-0625.2009.00982.x","volume":"19","author":"TM J\u00e4rvinen","year":"2010","unstructured":"J\u00e4rvinen TM, et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol. 2010;19(2):123\u201331. https:\/\/doi.org\/10.1111\/j.1600-0625.2009.00982.x.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1742_CR29","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","volume":"166","author":"I Braunstein","year":"2012","unstructured":"Braunstein I, Klein R, Okawa J, Werth VP. The interferon\u2010regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous Lupus area and severity index score. Br J Dermatol. 2012;166(5):971\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10825.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1742_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/bjd\/ljaf293","volume":"193","author":"S Wasserer","year":"2025","unstructured":"Wasserer S, et al. Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus. Br J Dermatol. 2025;193(6):1192\u2013203. https:\/\/doi.org\/10.1093\/bjd\/ljaf293.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1742_CR31","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1038\/jid.2008.96","volume":"128","author":"J Wenzel","year":"2008","unstructured":"Wenzel J, T\u00fcting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u2018interface dermatitis.\u2019 J Invest Dermatol. 2008;128(10):2392\u2013402. https:\/\/doi.org\/10.1038\/jid.2008.96.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1742_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/j.1365-2133.2005.06784.x","volume":"153","author":"J Wenzel","year":"2005","unstructured":"Wenzel J, Uerlich M, Worrenkamper E, Freutel S, Bieber T, Tuting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153(5):1011\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06784.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1742_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.autrev.2004.10.003","volume":"4","author":"RD Sontheimer","year":"2005","unstructured":"Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4(5):253\u201363. https:\/\/doi.org\/10.1016\/j.autrev.2004.10.003.","journal-title":"Autoimmun Rev"},{"key":"1742_CR34","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.25.221309","author":"R Batra","year":"2020","unstructured":"Batra R, et al. Integration of phenomics and transcriptomics data to reveal drivers of inflammatory processes in the skin. Immunology. 2020. https:\/\/doi.org\/10.1101\/2020.07.25.221309.","journal-title":"Immunology"},{"issue":"1","key":"1742_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.13435","volume":"16","author":"IM Catlett","year":"2023","unstructured":"Catlett IM, et al. First\u2010in\u2010human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023;16(1):151\u201364. https:\/\/doi.org\/10.1111\/cts.13435.","journal-title":"Clin Transl Sci"},{"issue":"502","key":"1742_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736. https:\/\/doi.org\/10.1126\/scitranslmed.aaw1736.","journal-title":"Sci Transl Med"},{"issue":"20","key":"1742_CR37","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62(20):8973\u201395. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00444.","journal-title":"J Med Chem"},{"key":"1742_CR38","doi-asserted-by":"publisher","first-page":"154605","DOI":"10.1016\/j.cyto.2018.11.022","volume":"132","author":"GA Hile","year":"2020","unstructured":"Hile GA, Gudjonsson JE, Kahlenberg JM. The influence of interferon on healthy and diseased skin. Cytokine. 2020;132:154605. https:\/\/doi.org\/10.1016\/j.cyto.2018.11.022.","journal-title":"Cytokine"},{"issue":"8","key":"1742_CR39","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jid.2018.02.034","volume":"138","author":"F Lauffer","year":"2018","unstructured":"Lauffer F, et al. Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis. J Invest Dermatol. 2018;138(8):1785\u201394. https:\/\/doi.org\/10.1016\/j.jid.2018.02.034.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1742_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.rdc.2009.12.008","volume":"36","author":"MK Crow","year":"2010","unstructured":"Crow MK. Interferon-alpha: a therapeutic target in Systemic Lupus Erythematosus. Rheum Dis Clin N Am. 2010;36(1):173\u201386. https:\/\/doi.org\/10.1016\/j.rdc.2009.12.008.","journal-title":"Rheum Dis Clin N Am"},{"issue":"8","key":"1742_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/08916930310001625952","volume":"36","author":"MK Crow","year":"2003","unstructured":"Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36(8):481\u201390. https:\/\/doi.org\/10.1080\/08916930310001625952.","journal-title":"Autoimmunity"},{"issue":"642","key":"1742_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2263","volume":"14","author":"AC Billi","year":"2022","unstructured":"Billi AC, et al. Nonlesional Lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci Transl Med. 2022;14(642):eabn2263. https:\/\/doi.org\/10.1126\/scitranslmed.abn2263.","journal-title":"Sci Transl Med"},{"issue":"7909","key":"1742_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","volume":"605","author":"GJ Brown","year":"2022","unstructured":"Brown GJ, et al. TLR7 gain-of-function genetic variation causes human Lupus. Nature. 2022;605(7909):349\u201356. https:\/\/doi.org\/10.1038\/s41586-022-04642-z.","journal-title":"Nature"},{"key":"1742_CR44","unstructured":"Bristol-Myers Squibb. US National Library of Medicine. ClinicalTrials.gov Identifier: NCT04857034. A study to evaluate efficacy and safety of deucravacitinib in participants with active discoid and\/or subacute cutaneous lupus erythematosus (DLE\/SCLE). https:\/\/clinicaltrials.gov\/study\/NCT04857034. Accessed  10 Aug 2025."},{"key":"1742_CR45","unstructured":"Bristol-Myers Squibb. US National Library of Medicine. ClinicalTrials.gov Identifier: NCT06875960. A study to continue the administration of deucravacitinib in participants with systemic lupus erythematosus (SLE) or discoid and\/or subacute cutaneous lupus erythematosus (DLE\/SCLE) who have completed study IM011074 or study IM011132. https:\/\/clinicaltrials.gov\/study\/NCT06875960?cond=NCT06875960&rank=1. Accessed 30 Mar 2026."},{"key":"1742_CR46","unstructured":"Bristol-Myers Squibb. US National Library of Medicine. ClinicalTrials.gov Identifier: NCT03920267. Long-term safety and efficacy study of deucravacitinib in participants with systemic lupus erythematosus. https:\/\/clinicaltrials.gov\/study\/NCT03920267?cond=NCT03920267&rank=1. Accessed 20 Mar 2026."},{"issue":"2","key":"1742_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/srt.12636","volume":"25","author":"F Lacarrubba","year":"2019","unstructured":"Lacarrubba F, Verz\u00ec AE, Caltabiano R, Broggi G, Natale AD, Micali G. Discoid Lupus Erythematosus: reflectance confocal microscopy features correlate with horizontal histopathological sections. Skin Res Technol. 2019;25(2):242\u20134. https:\/\/doi.org\/10.1111\/srt.12636.","journal-title":"Skin Res Technol"},{"issue":"1","key":"1742_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/0961203320958141","volume":"30","author":"S Mazzilli","year":"2021","unstructured":"Mazzilli S, et al. The combined role of clinical, reflectance confocal microscopy and dermoscopy applied to chronic discoid cutaneous Lupus and subacutus Lupus erythematosus: a case series and literature review. Lupus. 2021;30(1):125\u201333. https:\/\/doi.org\/10.1177\/0961203320958141.","journal-title":"Lupus"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01742-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01742-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01742-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:54Z","timestamp":1780584834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01742-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1742"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01742-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paola Facheris has served as a consultant for Eli Lilly and as a speaker for UCB, AbbVie, and Pfizer. Marco Ardig\u00f2 has received consulting fees from Pierre Fabre and has participated in lectures, presentations, and advisory boards for Almirall, Kyowa Kirin, Pierre Fabre, Recordati Rare Diseases, and Cantabria Labs. Antonio Costanzo has served as an advisory board member and consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB. Mario Valenti has served as a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, Boehringer Ingelheim, Almirall, UCB, and Difa Cooper. Mario Valenti is a member of the Editorial Board of\n                      Dermatology and Therapy\n                      . Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Francesco D\u2019Oria, Francesco Piscazzi, and Giulio Foggi declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Written informed consent was obtained from the patient for publication of clinical information and images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}